Correlation found between change in IOP and conjunctival hyperaemia induced by latanoprost

Article

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study.

A strong correlation between a change in intraocular pressure (IOP) and conjunctival hyperaemia severity induced by latanoprost has been confirmed in a recent study published in the Journal of Glaucoma.

Drs Hiroshi and Kaori Kobayashi, from Amagasaki Hospital, Hyogo and Osaka Red Cross Hospital, Osaka, Japan, respectively, examined 114 patients with open-angle glaucoma or ocular hypertension. Their aim was to determine any correlation between a short-term change in conjunctival hyperaemia severity and the IOP-reducing effect induced by latanoprost.

Of the 114 patients 56 were female and 58 were male and they had a mean age of 60.9±15 years. The primary outcome of the study was to determine the change in conjunctival hyperaemia grade at day 2 and the change in IOP at 6 months after commencing latanoprost treatment.

The mean IOP before latanoprost treatment was 22.5±3.8 mmHg and after 6 months it was 16.5±2.9 mmHg (P < 0.0001). Mean changes in conjunctival hyperaemia before and after 2 days of latanoprost treatment were 0.32±0.58 and 1.74±1.11, respectively (P < 0.0001). It was found that the mean change in IOP was greater in eyes with a higher hyperaemia grade change.

In conclusion, the researchers found a significant correlation between the change in IOP and the conjunctival hyperaemia severity after treatment with latanoprost.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.